GlassScriptPhysician profile
Joseph Romero
NPI 1235461914
$59,806.65
in general payments reported to CMS, 2019-2025
28 companies · $16K in 2025
The $16K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $172 · 2021: $5,117 · 2022: $907 · 2023: $20K · 2024: $18K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $46K · Food and Beverage: $4,316 · Travel and Lodging: $2,342 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $46,000.00 |
| Food and Beverage | $4,316.40 |
| Travel and Lodging | $2,341.87 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $57,391.97 | 2021-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Gilead Sciences, INC. | $572.64 | 2019-2025 | Descovy, Yeztugo |
| Insmed, INC. | $319.60 | 2019-2023 | Arikayce |
| Glaxosmithkline, LLC. | $231.37 | 2019-2025 | Trelegy Ellipta, Nucala |
| Inari Medical, INC. | $190.84 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Galvanize Therapeutics, INC | $187.51 | 2025 | Aliya System |
| Medline Industries LP | $108.08 | 2021 | |
| Pulmonx Corporation | $108.06 | 2019-2023 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Vapotherm INC | $67.37 | 2022-2023 | Vapotherm |
| Actelion Pharmaceuticals US, INC. | $61.58 | 2019-2021 | |
| Abbott Laboratories | $57.33 | 2024 | Proclaim |
| Grifols USA, LLC | $53.60 | 2023-2025 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals LP | $48.26 | 2023-2025 | Fasenra, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.35 | 2019-2023 | Ofev |
| Ethicon INC. | $42.66 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $41.22 | 2019 | |
| Amgen INC. | $37.29 | 2024 | Tezspire |
| Viiv Healthcare Company | $31.85 | 2024 | Dovato |
| Harmony Biosciences LLC | $31.37 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $29.69 | 2024 | Dupixent |
| Baxter Healthcare | $23.49 | 2022 | |
| Merck Sharp & Dohme LLC | $22.76 | 2025 | Winrevair |
| Sunovion Pharmaceuticals INC. | $22.30 | 2019 | |
| Nuwellis, INC. | $19.26 | 2019 | |
| Allergan, INC. | $18.64 | 2019 | |
| Boston Scientific Corporation | $17.46 | 2022 | |
| Genentech USA, INC. | $15.80 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Romero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.